Xencor（XNCR）株式概要
臨床段階のバイオ医薬品企業であるゼンコール社は、癌や自己免疫疾患の治療のための人工抗体の発見と開発に注力している。 詳細
XNCR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Xencor, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$29.00 |
| 52週高値 | US$29.42 |
| 52週安値 | US$7.71 |
| ベータ | 0.84 |
| 1ヶ月の変化 | 49.15% |
| 3ヶ月変化 | 149.31% |
| 1年変化 | 261.99% |
| 3年間の変化 | 28.01% |
| 5年間の変化 | -14.47% |
| IPOからの変化 | 247.66% |
最新ニュース
分析記事 • Aug 15
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Celebrations may be in order for Xencor, Inc. ( NASDAQ:XNCR ) shareholders, with the analysts delivering a significant...分析記事 • Aug 08
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. ( NASDAQ:XNCR ) just released its quarterly report and things are looking bullish. Revenue crushed...Seeking Alpha • Jul 14
Xencor: Bullish On Their Increasingly In-House Pipeline
Summary Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR’s oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR’s valuation in the near term. I believe XNCR’s balance sheet is enough to finance its near-term milestones. The wildcard is how much cash burn increases once pivotal trials commence. Ultimately, I remain bullish on the stock because XNCR has several programs that can create significant shareholder value if successful. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 10
XNCR: Q2 Rebound Risk And Softer Start To Year May Drive Downside
Analysts recently adjusted their price targets on Xencor, with changes such as Truist moving to $27 and others raising targets by $1. These updates reflect revised models that factor in expectations for a Q2 rebound, a more supportive catalyst calendar, and sector-wide optimism.Recent updates
分析記事 • Aug 15
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts
Celebrations may be in order for Xencor, Inc. ( NASDAQ:XNCR ) shareholders, with the analysts delivering a significant...分析記事 • Aug 08
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results
Xencor, Inc. ( NASDAQ:XNCR ) just released its quarterly report and things are looking bullish. Revenue crushed...Seeking Alpha • Jul 14
Xencor: Bullish On Their Increasingly In-House Pipeline
Summary Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR’s oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR’s valuation in the near term. I believe XNCR’s balance sheet is enough to finance its near-term milestones. The wildcard is how much cash burn increases once pivotal trials commence. Ultimately, I remain bullish on the stock because XNCR has several programs that can create significant shareholder value if successful. Read the full article on Seeking Alphaナラティブ更新 • Jul 10
XNCR: Q2 Rebound Risk And Softer Start To Year May Drive Downside
Analysts recently adjusted their price targets on Xencor, with changes such as Truist moving to $27 and others raising targets by $1. These updates reflect revised models that factor in expectations for a Q2 rebound, a more supportive catalyst calendar, and sector-wide optimism.
ナラティブ更新 • Jun 12
XNCR: Future Regulatory Stability And TL1A Pipeline Progress Will Drive Upside
Analysts have adjusted their price target on Xencor by $1, reflecting updated views on the stock after recent research that both lifted the target and questioned the near term catalyst path. Analyst Commentary Bullish Takeaways Bullish analysts highlight the recent US$1 price target adjustment as a signal that updated research still supports upside potential for the stock relative to their prior view.ナラティブ更新 • May 29
XNCR: Future Regulatory Shifts Will Support Oncology Execution Upside
Analysts now estimate Xencor's fair value at about $28.50 per share, a modest change from roughly $28.83 as they factor in updated expectations for revenue growth, profit margins and future P/E following recent price target and rating moves on the stock. Analyst Commentary Recent Street research on Xencor reflects a mix of cautious and constructive views, with JPMorgan adjusting its stance and price target as expectations for catalysts and execution evolve.分析記事 • May 11
These Analysts Just Made A Huge Downgrade To Their Xencor, Inc. (NASDAQ:XNCR) EPS Forecasts
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...
ナラティブ更新 • May 02
XNCR: Refined Q4 Assumptions And Regulatory Shifts Will Drive Future Repricing
Analysts have kept Xencor's fair value estimate steady at $43.00, while modestly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E after recent research. This research includes a $1 price target increase to $27 from $26.00, alongside a downgrade based on expectations for fewer near term catalysts.ナラティブ更新 • Apr 18
XNCR: Mixed Catalyst Outlook And Regulatory Shifts Will Shape Future Repricing
Analysts have increased their price target on Xencor by $1 to $27, citing updated models after the Q4 report, even as some see limited near term catalysts to significantly change the story. Analyst Commentary Recent research on Xencor reflects a more cautious tone, with some high profile firms highlighting limited catalysts and execution risk, even as models are refreshed following the Q4 report.ナラティブ更新 • Apr 03
XNCR: T Cell Engagers And Mixed Catalyst Outlook Will Shape Multi Year Repricing
Narrative Update The analyst fair value estimate for Xencor has been reset from $18.00 to $13.00 as analysts factor in a lack of near term, needle moving catalysts highlighted in recent research, along with updated models following the Q4 report and sector wide reassessments of U.S. biopharmaceutical valuations. Analyst Commentary Recent Street research on Xencor reflects a mix of views, and the reset in fair value has been driven mainly by more cautious commentary around the near term outlook and the timing of impactful catalysts.ナラティブ更新 • Mar 20
XNCR: Sector Tailwinds And T Cell Engagers Will Drive Multi Year Repricing
Analysts have nudged their Xencor models after recent sector-wide updates and the latest Q4 report, with Street price targets moving into a roughly $20 to $27 range. The internal fair value anchor in this framework holds near $18, reflecting tempered revenue and margin assumptions offset by supportive biopharma sentiment.ナラティブ更新 • Mar 06
XNCR: Reset Pipeline Milestones And Sector Tailwinds Will Drive Repricing
Analysts have raised their Xencor fair value estimate from $40.00 to $43.00, reflecting refreshed models and higher Street price targets, including recent moves to $27 and $20, supported by updated company assumptions and broader biotech sector drivers cited in recent research. Analyst Commentary Recent Street research on Xencor points to a more constructive stance on the stock, with bullish analysts revisiting their models after the latest quarterly update and broader sector checks.ナラティブ更新 • Feb 20
XNCR: T Cell Engagers In Solid Tumors Will Drive Multi Year Repricing
Analysts raised their Xencor price target to $20 from $17, citing an improving environment for U.S. biotech funding and deal activity, as well as greater market recognition of recent positive data catalysts. Analyst Commentary Recent commentary around Xencor frames the higher US$20 price target within a broader reassessment of U.S. biopharmaceutical names.分析記事 • Feb 13
Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate
Key Insights Xencor's estimated fair value is US$16.09 based on 2 Stage Free Cash Flow to Equity Xencor's US$11.62...ナラティブ更新 • Feb 06
XNCR: Constructive Biopharma Backdrop Will Support Future Oncology Upside
Narrative Update Analysts have nudged their 12 month price target for Xencor higher from US$17 to US$20, citing a more constructive backdrop for U.S. biopharmaceuticals, improving access to capital, supportive M&A activity, and recent positive data catalysts now being reflected in valuations. Analyst Commentary Recent commentary around Xencor centers on how it fits into a broader recovery in U.S. biopharmaceuticals, with the new US$20 price target reflecting both improved sector conditions and ongoing uncertainty about how durable these supports will be.ナラティブ更新 • Jan 23
XNCR: T Cell Engagers And TL1A Pipeline Will Drive Multi Year Repricing
Analysts have nudged their price targets on Xencor higher to a range of US$20 to US$42, pointing to positive recent data readouts, a more constructive view on the T cell engager and TL1A pipeline, and a generally more supportive biotech funding backdrop. Analyst Commentary Recent Street research on Xencor clusters around a more constructive view of its T cell engager and TL1A programs, but opinions are not uniformly bullish.ナラティブ更新 • Jan 08
XNCR: T Cell Engager Pipeline Progress Will Drive Multi Year Repricing Potential
Narrative Update Analysts have lifted their Xencor fair value estimate from US$8.67 to US$18.00. This change reflects higher Street price targets in the US$20 to US$42 range and growing confidence in the company's T cell engager pipeline following recent data updates and conference presentations.ナラティブ更新 • Dec 18
XNCR: Advancing T Cell Engagers Will Drive Future Oncology Upside
We are nudging our Xencor fair value estimate slightly higher to $28.25 from $28.00, reflecting analysts' increased price targets and improved sentiment around the company's T cell engager and TL1A antibody programs following encouraging early stage data and clearer late stage development visibility. Analyst Commentary Recent Street research reflects a constructive but still risk balanced view on Xencor, with multiple firms lifting price targets as they factor in stronger T cell engager data and growing conviction in the TL1A program, while still highlighting execution and clinical readout risks that could impact long term value realization.ナラティブ更新 • Dec 04
XNCR: Advancing T Cell Engager Pipeline Will Drive Future Upside Potential
Xencor's analyst price target has inched higher to about $28.00 from roughly $27.91, as analysts factor in stronger long term value from the company's advancing T cell engager and TL1A antibody programs, despite modest tweaks to growth and margin assumptions. Analyst Commentary Recent Street research reflects a generally improving stance on Xencor, with several bullish analysts lifting price targets as confidence grows in the company’s T cell engager and TL1A programs, while more cautious voices continue to emphasize execution and clinical risk.分析記事 • Nov 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shares have continued their recent momentum with a 27% gain in the last month alone...ナラティブ更新 • Nov 20
XNCR: Advancing Late-Stage Antibody Programs Will Drive Upside Into 2025
The analyst price target for Xencor edged higher to $27.91 from $27.64 after analysts cited improved revenue growth outlook and progress across key clinical programs. Analyst Commentary Recent Street research on Xencor reflects a range of views, with several analysts updating their models and outlooks following new data from clinical programs and company updates.ナラティブ更新 • Nov 05
XNCR: Positive Early Oncology Data Will Accelerate Future Upside Potential
Xencor's analyst price target has increased from $25.73 to $27.64, with analysts citing positive pipeline updates and an improved outlook on novel oncology programs as drivers of the higher valuation. Analyst Commentary Analyst sentiment on Xencor has shifted notably in recent months, reflecting emerging data from clinical studies and evolving perspectives on the company's future growth potential.ナラティブ更新 • Oct 22
Analysts Weigh Xencor Pipeline Progress as Price Targets Inch Higher on Positive Data
The analyst price target for Xencor has increased modestly, rising by $0.18 per share as analysts cite encouraging initial data for its XmAb819 therapy and a slightly improved outlook on pipeline progress, despite ongoing development challenges. Analyst Commentary Recent Street research provides a mixed outlook on Xencor, reflecting both optimism around its emerging therapies and caution due to the company's ongoing development challenges and market execution risks.ナラティブ更新 • Oct 08
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have raised their price target for Xencor from $24.10 to $25.55 per share. This reflects moderate optimism despite concerns around limited near-term catalysts and extended development timelines described in recent research commentary.分析記事 • Sep 25
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 31% Share Price Rise
Xencor, Inc. ( NASDAQ:XNCR ) shareholders have had their patience rewarded with a 31% share price jump in the last...分析記事 • Sep 18
Health Check: How Prudently Does Xencor (NASDAQ:XNCR) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブ更新 • Aug 22
IBD Biologics And TL1A Programs Will Forge New Paths
Analysts have reduced their price target for Xencor to $25.20 amid optimism for key pipeline assets but tempered by concerns over limited data, lack of near-term catalysts, and execution speed. Analyst Commentary Stock price seen as undervaluing Xencor's three main business pillars: IBD franchise led by '942, immunology efforts led by plamotamab, and the oncology bispecific platform.分析記事 • Aug 06
Xencor, Inc.'s (NASDAQ:XNCR) Price Is Right But Growth Is Lacking
NasdaqGM:XNCR 1 Year Share Price vs Fair Value Explore Xencor's Fair Values from the Community and select yours With a...新しいナラティブ • Jul 06
IBD Biologics And TL1A Programs Will Forge New Paths
Differentiated drug design and flexible development platform position Xencor for increased patient adoption, operational efficiency, and attractive long-term profitability.分析記事 • Apr 26
Is Xencor (NASDAQ:XNCR) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Mar 30
Xencor, Inc. (NASDAQ:XNCR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely
To the annoyance of some shareholders, Xencor, Inc. ( NASDAQ:XNCR ) shares are down a considerable 27% in the last...分析記事 • Feb 04
Some Confidence Is Lacking In Xencor, Inc. (NASDAQ:XNCR) As Shares Slide 27%
Xencor, Inc. ( NASDAQ:XNCR ) shares have had a horrible month, losing 27% after a relatively good period beforehand...Seeking Alpha • Jan 30
Xencor: Substantial Promise, Slow Progress
Summary Today, I revisit Xencor, Inc., a developmental biotech concern for the first time since 2017. The company is advancing a diverse pipeline that consists of both licensed and wholly owned candidates. Xencor has a strong cash position, projecting $707 million in cash and marketable securities by year-end, bolstered by a recent $200 million secondary offering. Xencor's pipeline has some significant promise, but progress has been notably slow over the years. An updated analysis around Xencor follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Dec 31
Is Xencor (NASDAQ:XNCR) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Dec 03
Xencor, Inc.'s (NASDAQ:XNCR) 26% Share Price Surge Not Quite Adding Up
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 26% in the...分析記事 • Nov 10
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders of Xencor, Inc. ( NASDAQ:XNCR ) will be pleased this week, given that the stock price is up 11% to...Seeking Alpha • Sep 12
Xencor: Vudalimab Development Along With Hidden Gem Candidate
Summary Monotherapy and combination dose cohort data from the phase 2 study, using vudalimab for the treatment of patients with mCRPC, expected 1st half of 2025. The global metastatic castrate-resistant prostate cancer treatment market size is projected to reach $20.70 billion by 2031. XmAb942 is a candidate in the company's pipeline which has the potential to become the best in class anti-TL1A inhibitor for the treatment of autoimmune disorders like UC and CD. The global market for inflammatory bowel disease is expected to cross $30 billion by 2031. Read the full article on Seeking Alpha分析記事 • Sep 12
Xencor, Inc.'s (NASDAQ:XNCR) 34% Share Price Surge Not Quite Adding Up
Xencor, Inc. ( NASDAQ:XNCR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...分析記事 • Sep 06
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR)
Key Insights The projected fair value for Xencor is US$16.92 based on 2 Stage Free Cash Flow to Equity With US$16.32...分析記事 • Jul 13
Does Xencor (NASDAQ:XNCR) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jun 16
Lacklustre Performance Is Driving Xencor, Inc.'s (NASDAQ:XNCR) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 7.8x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...分析記事 • Mar 27
Is Xencor (NASDAQ:XNCR) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Feb 27
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 29% Share Price Rise
Despite an already strong run, Xencor, Inc. ( NASDAQ:XNCR ) shares have been powering on, with a gain of 29% in the...Seeking Alpha • Feb 03
Xencor: Standing Out With XmAb Technology
Summary Xencor demonstrates strong YoY revenue growth through achieved milestones with major industry partners. The strategic sale of royalty interests strengthens Xencor's balance sheet and provides flexibility for future strategic moves. Xencor's pipeline developments and clinical trials show a focus on promising therapies in oncology and autoimmune diseases. Read the full article on Seeking Alpha分析記事 • Jan 05
Xencor, Inc.'s (NASDAQ:XNCR) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 9.3x Xencor, Inc. ( NASDAQ:XNCR ) is a stock worth...分析記事 • Nov 13
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Xencor, Inc. ( NASDAQ:XNCR ) - they aren't optimistic, having just made a...分析記事 • Nov 10
Companies Like Xencor (NASDAQ:XNCR) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Aug 08
Party Time: Brokers Just Made Major Increases To Their Xencor, Inc. (NASDAQ:XNCR) Earnings Forecasts
Shareholders in Xencor, Inc. ( NASDAQ:XNCR ) may be thrilled to learn that the analysts have just delivered a major...株主還元
| XNCR | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 25.4% | 6.3% | -1.2% |
| 1Y | 262.0% | 47.2% | 18.3% |
業界別リターン: XNCR過去 1 年間で47.2 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: XNCR過去 1 年間で18.3 % の収益を上げたUS市場を上回りました。
価格変動
| XNCR volatility | |
|---|---|
| XNCR Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: XNCR 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: XNCRの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1997 | 260 | Bassil Dahiyat | www.xencor.com |
Xencor社は臨床段階にあるバイオ医薬品企業で、癌や自己免疫疾患の治療のための人工抗体の発見と開発に注力している。同社は、非定型溶血性尿毒症症候群、重症筋無力症、視神経脊髄炎スペクトラム障害の治療薬としてウルトミリスを、再発または難治性のびまん性大細胞型B細胞リンパ腫の治療薬としてモンジュビを提供している。また、腎細胞がん治療用の二重特異性抗体XmAb819、卵巣がん治療用のフェーズI段階にあるXmAb541、広範に発現する腫瘍抗原に結合する二重特異性抗体XmAb808も開発しています；クローン病や潰瘍性大腸炎患者を対象に臨床開発中のXmAb942、関節リウマチ治療薬として第Ib相試験中の二特異性T細胞であるプラモタマブ、特発性炎症性ミオパチー患者を対象としたXmAb657。さらに、前立腺がんを治療する二重特異性T細胞エンゲイジャーXaluritamig、胃がん、胃食道接合部がん、膵臓がんを治療するASP2138、転移性去勢抵抗性前立腺がんを治療するJNJ-9401、自己免疫疾患患者を治療する抗体Obexelimabを開発している；慢性肝炎デルタ治療薬Tobevibart、発作性夜間ヘモグロビン尿症およびその他の代替経路障害治療薬Zaltenibart、ヒト免疫不全ウイルス治療薬Teropavimabおよびzinlirvimab、XmAb Fc技術を用いた抗体医薬品候補Novartis、B細胞悪性腫瘍治療薬JNJ-1493。同社は1997年に設立され、カリフォルニア州パサデナに本社を置いている。
Xencor, Inc. 基礎のまとめ
| XNCR 基礎統計学 | |
|---|---|
| 時価総額 | US$2.07b |
| 収益（TTM） | -US$163.32m |
| 売上高(TTM) | US$104.97m |
20.5x
P/Sレシオ-13.2x
PER（株価収益率XNCR は割高か？
公正価値と評価分析を参照収益と収入
| XNCR 損益計算書（TTM） | |
|---|---|
| 収益 | US$104.97m |
| 売上原価 | US$255.77m |
| 売上総利益 | -US$150.79m |
| その他の費用 | US$12.53m |
| 収益 | -US$163.32m |
直近の収益報告
Jun 30, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.20 |
| グロス・マージン | -143.65% |
| 純利益率 | -155.59% |
| 有利子負債／自己資本比率 | 20.8% |
XNCR の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/24 23:23 |
| 終値 | 2026/08/24 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Xencor, Inc. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。25
| アナリスト | 機関 |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Zhiqiang Shu | Berenberg |